Last data update: 2014.03.03

Data Source

R Release (3.2.3)
CranContrib
BioConductor
All

Data Type

Packages
Functions
Images
Data set

Classification

Results 1 - 5 of 5 found.
[1] < 1 > [1]  Sort:

dpwdg (Package: ICEinfer) : Output list object of class ICEwedge for the High Uncertainty example, data(dulxparx)

dpwdg is the output list object of class ICEwdg resulting from the following time consuming computation: dpwdg <- ICEwedge(dpunc)
● Data Source: CranContrib
● Keywords: datasets
● Alias: dpwdg
1 images

fluoxpin (Package: ICEinfer) : Data from a double-blind clinical trial comparing fluoxetine plus pindolol with fluoxetine alone

These data are from a Spanish double-blind clinical trial in which 55 patients were randomized to fluoxetine (an SSRI) plus pindolol (a Beta Blocker) and 56 patients were randomized to fluoxetine plus placebo for treatment of major depressive disorder (MDD), Sacristan et al. (2000).
● Data Source: CranContrib
● Keywords: datasets
● Alias: fluoxpin
10 images

dpunc (Package: ICEinfer) :

dpunc is the output list object of class ICEuncrt resulting from the following time consuming computation: dpunc <- ICEuncrt(dulxparx, dulx, idb, ru, lambda=0.26)
● Data Source: CranContrib
● Keywords: datasets
● Alias: dpunc
1 images

dulxparx (Package: ICEinfer) : Data for the High Uncertainty numerical example of Obenchain et al. (2005)

The data are from two arms of a double-blind clinical trial in which 91 patients were randomized to the SNRI duloxetine 80 mg/d (40 mg BID) and 87 patients were randomized to the SSRI paroxetine 20 mg/d for treatment of major depressive disorder (MDD). Missing-data- imputation and sensitivity-analyses were needed to make meaningful cost-effectiveness comparisons in this study.
● Data Source: CranContrib
● Keywords: datasets
● Alias: dulxparx
10 images

fluoxtca (Package: ICEinfer) : Cost-Effectiveness data for 1242 MDD patients from Marketscan(SM) claims database

In 1990-1992, the Marketscan(SM) database included medical and pharmacy claims for approximately 700,000 individuals whose health insurance was provided by large corporations throughout the United States. Outcomes for 1242 patients treated with either fluoxetine (SSRI) or with a TCA / HCA for major depressive disorder (MDD) were discussed in Croghan et al. (1996) and Obenchain et al. (1997). All 1242 patients were continuously enrolled for at least 4 months prior to their initial antidepressant prescription and for the following 12 months.
● Data Source: CranContrib
● Keywords: datasets
● Alias: fluoxtca
10 images